Glen Donovan - 08 Dec 2021 Form 4 Insider Report for PPD, Inc.

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
08 Dec 2021, 15:40:25 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Richard Whitlow, as Attorney-in-Fact

Key filing fact

Glen Donovan filed Form 4 for PPD, Inc. on 08 Dec 2021.

Key facts

  • This page summarizes Glen Donovan's Form 4 filing for PPD, Inc..
  • 11 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 08 Dec 2021, 15:40.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: -$2,447,062.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PPD transaction

Common Stock

Disposed to Issuer

Transaction value
$142,500
Shares
-3,000
Change %
-100%
Price
$47.50
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Footnotes
F1, F2
PPD transaction

Common Stock

Award

Transaction value
$0
Shares
+8,182
Change %
Price
$0.000000
Shares after
8,182
Date
08 Dec 2021
Ownership
Direct
Footnotes
F1, F3
PPD transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-8,182
Change %
-100%
Price
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Footnotes
F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PPD transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
$1,798,509
Shares
-55,424
Change %
-100%
Price
$32.45
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
55,424
Exercise price
$15.05
Footnotes
F1, F4
PPD transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
$0
Shares
+7,974
Change %
Price
$0.000000
Shares after
7,974
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,974
Exercise price
$10.59
Footnotes
F5
PPD transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
$294,320
Shares
-7,974
Change %
-100%
Price
$36.91
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,974
Exercise price
$10.59
Footnotes
F5
PPD transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
$0
Shares
+2,271
Change %
+150%
Price
$0.000000
Shares after
3,785
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,271
Exercise price
$19.24
Footnotes
F6
PPD transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
$106,964
Shares
-3,785
Change %
-100%
Price
$28.26
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,785
Exercise price
$19.24
Footnotes
F5, F6
PPD transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
$104,769
Shares
-3,785
Change %
-100%
Price
$27.68
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,785
Exercise price
$19.82
Footnotes
F1, F7
PPD transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-859
Change %
-100%
Price
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
859
Exercise price
$26.82
Footnotes
F1, F8
PPD transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-8,487
Change %
-100%
Price
Shares after
0
Date
08 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,487
Exercise price
$37.22
Footnotes
F1, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Glen Donovan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 9 footnotes

Footnote F1

On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

Footnote F2

At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Footnote F3

Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger.

Footnote F4

These options, of which 7,973 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

Footnote F5

These options, which were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

Footnote F6

This option, of which 2,271 were eligible to vest in equal installments upon the achievement of certain EBITDA-based vesting conditions for each of the fiscal years 2021, 2022, and 2023 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

Footnote F7

This option, which provided for vesting in four equal installments beginning on August 23, 2020, was canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

Footnote F8

This option, which provided for vesting in four equal installments beginning on May 13, 2021, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement.

Footnote F9

This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .